EPI-SENSE-AF GUIDED COAGULATION SYSTEM
Device
ATRICURE, INC.
Total Payments
$58,833
Transactions
43
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $58,833 | 43 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $58,833 | 43 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CONVERGENCE OF EPICARDIAL AND ENDOCARDIAL RF ABLATION FOR THE TREATMENT OF SYMPTOMATIC PERSISTENT AF | ATRICURE, INC. | $48,491 | 0 |
| CONVERGENCE OF EPICARDIAL AND ENDOCARDIAL RF ABLATION FOR THE TREATMENT OF SYMPTOMATIC PERSISTENT AF | AtriCure, Inc. | $10,343 | 2 |
Ad
Manufacturing Companies
- ATRICURE, INC. $48,491
- AtriCure, Inc. $10,343
Product Information
- Type Device
- Total Payments $58,833
- Total Doctors 2
- Transactions 43
About EPI-SENSE-AF GUIDED COAGULATION SYSTEM
EPI-SENSE-AF GUIDED COAGULATION SYSTEM is a device associated with $58,833 in payments to 2 healthcare providers, recorded across 43 transactions in the CMS Open Payments database. The primary manufacturer is ATRICURE, INC..
Payment data is available from 2020 to 2020. In 2020, $58,833 was paid across 43 transactions to 2 doctors.
The most common payment nature for EPI-SENSE-AF GUIDED COAGULATION SYSTEM is "Unspecified" ($58,833, 100.0% of total).
EPI-SENSE-AF GUIDED COAGULATION SYSTEM is associated with 2 research studies, including "CONVERGENCE OF EPICARDIAL AND ENDOCARDIAL RF ABLATION FOR THE TREATMENT OF SYMPTOMATIC PERSISTENT AF" ($48,491).